Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Short-Term Efficacy of Different First-Line Chemotherapy Regimens for Advanced Non-Small Cell LungCancer: A Network Meta-Analysis. This study intends to compare short-term efficacy of 12 chemotherapy regimens in treatment of advanced non-small cell lungcancer (NSCLC) by a network meta-analysis (NMA). PubMed, Cochrane Library, and Embase were searched from the inception of each database to June 2018. Randomized controlled trials (RCTs) of the 12 chemotherapy regimens for advanced NSCLC were (...) response rate (ORR), gemcitabine had poorer efficacy than cisplatin + gemcitabine and paclitaxel + gemcitabine. For disease control rate (DCR), compared with carboplatin + gemcitabine and gemcitabine, paclitaxel + gemcitabine had a better efficacy. Gemcitabine had the lowest SUCRA values in terms of complete response, PR, ORR, stable disease, and DCR; whereas paclitaxel + gemcitabine ranked the highest in ORR, progressive disease, and DCR. The cluster analysis revealed that cisplatin + gemcitabine
Identification of miR-210 and combination biomarkers as useful agents in early screening non-small cell lungcancer. Recently, extensive researches have explored the potential biomarker roles of microRNA-210 (miR-210) in non-small cell lungcancer (NSCLC). Inconsistent results, however, have prevented its widespread use in diagnosis. In the present study, we aimed to clarify the biomarker roles of miR-210 in NSCLC through a comprehensive meta-analysis and an integrative bioinformatics
Expression of autophagy-related factor p62 for lungcancer diagnosis and prognosis: A systematic review and meta-analysis. p62/SQSTM1 is the scaffold protein implicated in selective autophagy, which is induced by cellular stress. Research has shown that p62 is highly expressed in cancer. Moreover, p62 can easily promote tumor metastasis. However, studies have not reached a consensus on the relationship of p62 expression with the diagnosis and prognosis of lungcancer. We conducted a systematic (...) review and meta-analysis of studies on p62 expression in the prognosis and clinical-pathological parameters of lungcancer patients. Literature search was performed with PubMed, Web of Science, EMBASE, Cochrane Library, and SpringerLink databases. Fixed-effects and random-effects models were used to study the relationship of p62 expression with patients' overall survival (OS) and clinical-pathological parameters. I2 was used to test for heterogeneity. Egger's test was used to assess publication bias
Apatinib in the treatment of advanced non-small-cell lungcancer: A meta-analysis. Objectives: The purpose of this meta-analysis was to evaluate the efficacy and toxicity profile of apatinib for the treatment of advanced non-small cell lungcancer (NSCLC). Methods: We systematically searched databases for randomized clinical trials published as of November 25, 2017, in which apatinib treatment was compared to placebo or chemotherapy in patients with advanced NSCLC. Two investigators (...) independently assessed the articles and extracted their data. The hazard ratios (HRs) for progression-free survival (PFS), relative risks (RRs) for overall response rates (ORRs), disease control rates (DCRs), and odds ratios (ORs) for main toxicity were analyzed using the RevMan 5.3 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Results: Our analysis included 413 patients from 5 clinical studies. The pooled HR for PFS was 0.32 (95% confidence interval (CI) 0.21-0.48; P
Metformin improves survival in lungcancer patients with type 2 diabetes mellitus: A meta-analysis. In recent years, many studies have investigated metformin and its effects on lungcancer. However, since previous studies have shown that the relationship between metformin and lungcancer is complicated, we performed a meta-analysis to analyze this relationship.An electronic database search was conducted using PubMed, Embase, and Cochrane library. Outcomes were quantified with hazard ratios (...) and 95% confidence intervals to compare lungcancer survival in patients treated with or without metformin.Ten studies, involving 4397 participants, were included. In the pooled analysis, we found that metformin treatment significantly improved the survival of lungcancer patients (hazard ratio=0.75, 95% confidence interval: 0.70-0.80; P<0.001). Subgroup analysis showed that when stratified by geographic region, the hazard ratios for overall survival were 0.76 (95% confidence interval: 0.71-0.81, P
PD-L1 for selecting non-small-cell lungcancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. Aim: With the final aim to explore the first-line treatment options for non-small-cell lungcancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according
lungcancer cases were included in the analysis. The combined relative risks (RRs) with 95% CIs for the highest versus normal category of body mass index (BMI) were RR = 0.77 (95% CI: 0.72-0.82), but the inverse association disappeared for never smokers or small cell carcinoma after stratifying the smoking status or histological cancer types, respectively. Further analysis considered lag time and excluded the effects of preclinical cancer, there is no statistically significant inverse association (...) The Comparison of Different Obesity Indexes and the Risk of LungCancer: A Meta-Analysis of Prospective Cohort Studies. To evaluate the relationship between obesity, analyzed by different indicators, and lungcancer incidence, literature search was conducted in the PubMed, Web of Science, EBSCO, Ovid, and China National Knowledge Infrastructure databases for articles published until December 2018. Twenty-eight prospective cohort studies were identified, with 28 784,269 participants and 127,161
Association of Matrix Metalloproteinase1-1607 1G>2G Polymorphism and LungCancer Risk: An Update by Meta-Analysis. Objective: The association between matrix metalloproteinase1 (MMP1)-1607 1G>2G polymorphism and lungcancer
risk is still inconclusive and inconsistent. We conducted a meta-analysis to estimate the potential relationship between
MMP1-1607 1G>2G polymorphism and lungcancer risk. Methods: The comprehensive searches of the PubMed, Web
of Science, Medline, CBM, CNKI, Weipu (...) , and Wanfang databases, published up to Nov 10, 2018. Statistical analyses
were performed with Review Manager 5.3 software. Results: A total of 14 relevant studies containing 6068 cases and
5860 controls were included in the study. The results indicated that MMP1-1607 1G>2G polymorphism was significantly
associated with increased lungcancer risk under four models: 2G vs. 1G model (pooled OR = 1.19, 95% CI = 1.05-1.34,
P < 0.0001); 2G/2G vs. 1G/1G (pooled OR = 1.34, 95% CI = 1.09-1.64, P = 0.003); 2G/2G vs
The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lungcancer: a meta-analysis of 3112 patients. Aim: We performed a meta-analysis to explore the efficacy of immunotherapy for patients with squamous non-small-cell lungcancer (NSCLC). Materials & methods: Randomized clinical trials comparing immunotherapy with chemotherapy for advanced NSCLC patients were included. Results: A total of 11 trials (3112 patients) were included. PD-1/PD-L1 inhibitors demonstrated significant
Primary salivary gland-type tumors of the lung: A systematic review and pooled analysis. Primary salivary gland-type tumors of the lung (PSGTTL) are rare intrathoracic malignantneoplasms. Their description in literature is largely limited to a few case series and case reports. A systematic review and pooled analysis of the previously reported cases of PSGTTL is presented here.Electronic database of PubMed using keywords "lungneoplasm" AND "salivary gland tumors" was used to identify (...) ) (39.5%), and epithelial-myoepithelial cancer (3.8%). Tumors were located in the central airways (trachea and major bronchi) in 43.3% of patients. Weighted median tumor size was 4.2 cm. Surgery was the primary treatment undertaken in 82.4% of the patients, while radiotherapy and chemotherapy were also used in 15.9% and 9.4% of the patients. Lymph node involvement was seen in 15.2% of the patients. Disease recurrences were observed in 21.1% of the patients (12.9% and 37.5% in MEC and ACC, respectively
Clinical significance of miRNAâ€‘1 and its potential target gene network in lung squamous cell carcinoma. Previous studies demonstrated that miRNA‑1 (miR‑1) is downregulated in certain human cancer and serves a crucial role in the progression of cancer. However, there are only a few previous studies examining the association between miR‑1 and lung squamous cell carcinoma (LUSC) and the regulatory mechanism of miR‑1 in LUSC remains unclear. Therefore, the present study investigated the clinical
Association between serum zinc levels and lungcancer: a meta-analysis of observational studies. Inconsistent results according to numerous studies that had investigated the association between serum zinc levels and lungcancer risk were reported. The aim of this study was to explore whether serum zinc levels were lower in lungcancer patients than that in controls.We systematically retrieved the databases of PubMed, Wanfang, Cochrane, ScienceDirect website, CNKI, and SinoMed databases (...) for comprehensive relevant studies published before December 2018 and conducted a meta-analysis. Standard mean differences (SMD) were pooled using a random effects model.Thirty-two articles were eligible to investigate the correlation between serum zinc levels and lungcancer risk, involving 2894 cases and 9419 controls. The pooled results showed sufficient evidence approving the association between serum zinc levels and lungcancer risk. And the serum zinc levels in lungcancer were significantly lower than
-small-cell lungcancer" and "randomized controlled trial" as medical subject headings, the following electronic databases were searched: PubMed, EMBASE, Cochrane Library, and China National Knowledge Infrastructure. After data extraction and quality assessment of the included randomized controlled trials, the RevMan 5.3 software and R meta package were applied for meta-analysis of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS (...) Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lungcancer: a meta-analysis of the experimental evidence. Osimertinib is an EGFR-TKI that is selective for both EGFR-TKI-sensitizing and T790M resistance mutations in patients with non-small-cell lungcancer (NSCLC). The purpose of this study was conducting a meta-analysis to evaluate the clinical efficacy and safety of osimertinib in the treatment for NSCLC.Using "osimertinib" as a keyword combined with "non
Gene set enrichment analysis and meta-analysis identified 12 key genes regulating and controlling the prognosis of lungadenocarcinoma. The aim of the present study was to analyze lungadenocarcinoma-associated microarray data and identify potentially crucial genes. The gene expression profiles were downloaded from the Gene Expression Omnibus database and 6 datasets, of which 2 were discarded and 4 were retained, were preprocessed using packages in the R computing language. Subsequently, Gene (...) (DAVID) tool, and the pathways of crucial genes that were upregulated or downregulated were matched using the Venn method to identify the common crucial pathways. Furthermore, on the basis of the common crucial pathways, key genes that are closely associated with the development and progression of lungadenocarcinoma were identified with the KEGG pathway of DAVID. Additional information was obtained through Gene Ontology annotation. A total of two key pathways, including cell cycle and DNA
Preoperative anemia as a prognostic factor in patients with lungcancer: a systematic review and meta-analysis of epidemiological studies. The evidence of current epidemiological studies investigating the relationship between preoperative anemia and progression of lungcancer (LC) patients remains controversial. The PubMed, EMBASE, and Web of Science databases were comprehensively searched by two independent authors to identify related epidemiological studies from inception through January 31 (...) = 1.58; 95% CI = 1.44-1.75), with moderate heterogeneity (I2 = 53.1%). Funnel plot and statistical analyses showed no evidence of publication bias. Associations between pre-operative anemia and OS were broadly consistent across numerous subgroups analyses stratified by the study design, geographic location, number of cases, tumor, node, and metastasis (TNM) stage, histology, quality, and adjustment for potential confounders (age, sex, body mass index, TNM stage, histology, performance status, surgery
Prognostic value of microRNAs in lungcancer: A systematic review and meta-analysis. Lungcancer is one of the leading causes of cancer-associated mortality throughout the world. The prognosis of the disease depends on many factors including the stage and type of cancer. Many studies have identified various microRNAs (miRNAs) that affect the prognosis of lungcancer. In order to systemically analyze the available clinical data, the present study performed a meta-analysis to examine all evidence (...) on the potential role of miRNAs as novel predictors of survival in lungcancer. Literature published in English prior to February 1st, 2018 was searched through PubMed to review all of the associations between individual miRNAs and groups of miRNAs with the prognosis of lungcancer. Data was extracted using standard forms and pooled odds ratios with 95% confidence intervals (CIs) were calculated. A total of 15 eligible studies were included in the meta-analysis. These represented 1,753 lungcancer patients
The Association between Human Papillomavirus Infection and Smoking, Age, Gender in LungCancer Patients: A Meta-Analysis. The aim of our study was to identify the association between Human papillomavirus (HPV) positive rate and smoking in lungcancer (LC) patients. Meanwhile, to analyze differences among gender, age differences on HPV infection rate in LC patients.We performed a systematic literature search through PubMed, Wan Fang, China National Knowledge Infrastructure (CNKI), MEDLINE (...) , EMBASE (OVID), and Web of Science databases from 1991-2017, and we searched these keywords such as "lungcancer", "HPV", "smoking", and "human papillomavirus". Review Manager 5.3 software was used to analyze. An estimate of the odds ratio (OR) with 95% confidence intervals (CI) was calculated.In China, a statistical significance was observed between HPV positive rate and smoking in LC patients (OR=2.34, 95%CI: 1.76-3.09, P<0.001; I2 =25%). However, after stratified by region, no significance
, Web of Science, and Embase. Data were pooled using the number of events/number of evaluable patients (non-small cell lungcancer patients with BMs) according to fixed or random effect models. Intracranial efficacy was assessed through overall response rate (ORR), disease control rate (DCR), and median progression-free survival (PFS). Subgroup analyses for baseline BMs, previous treatment with ALK inhibitor, study type, and current ALK inhibitor were made.Twenty studies accounting for 2,715 (...) Anaplastic lymphoma kinase inhibitors in non-small cell lungcancer patients with brain metastases: a meta-analysis. Patients with anaplastic lymphoma kinase (ALK) rearrangements are particularly prone to development of brain metastases (BMs). Newer anti-ALK treatments have demonstrated far greater intracranial efficacy. Here we performed a meta-analysis with the aim of assessing the efficacy of ALK inhibitors on BMs.A search of published trials was conducted in PubMed, The Cochrane Library
Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lungcancer: a meta-analysis. Objective: This study aims to perform systematic review and meta-analysis of all randomized controlled trials that compare the efficacy and safety of programmed death 1 (PD-1) inhibitors versus chemotherapy alone in previously untreated advanced non-small cell lungcancer (NSCLC). Materials and methods: Several databases, including Medline, Cochrane Library, Embase